RTW INVESTMENTS, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001493215

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 81 positions · Total reported value $9.91B · Top-10 concentration 43.5% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 37.2% · 10 new · 12 cut · 13 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.3% · vs SPY -9.4% · Prev Value $11.71B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.7% · vs SPY -3.9% · Latest Value $9.91B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, RTW INVESTMENTS, LP disclosed 81 equity positions with a combined reported value of $9.91B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 43.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PTGX ($713.07M), ARGX ($682.35M), CGON ($603.60M). By sector, the heaviest allocations are Health Care 99.0%, Industrials 0.5%.

Versus the prior quarter, RTW INVESTMENTS, LP opened 10 new positions, trimmed 12 and fully exited 13, a turnover rate of 37.2% of positions. The portfolio's overlap with the prior quarter was 76% of names.

The largest new positions opened in Q3 2026 were VRDN ($102.03M), ANIX ($28.06M), PYXS ($15.16M).

Of the 13 positions fully exited versus the prior quarter, the largest were ALKS ($87.62M), DFTX ($18.82M), IDYA ($13.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • VRDN VIRIDIAN THERAPEUTICS INC · $102.03M
  • ANIX KORSANA BIOSCIENCES INC · $28.06M
  • PYXS PYXIS ONCOLOGY INC · $15.16M
  • SRZN SURROZEN INC · $12.66M
  • ARTV LATIGO BIOTHERAPEUTICS INC · $11.69M
  • SLN SILENCE THERAPEUTICS PLC · $7.65M
  • VNDA VANDA PHARMACEUTICALS INC · $5.98M
  • DYN DYNE THERAPEUTICS INC · $4.83M

Fully Exited (vs previous quarter)

  • ALKS ALKERMES PLC · prev qtr: $87.62M
  • DFTX DEFINIUM THERAPEUTICS INC · prev qtr: $18.82M
  • IDYA IDEAYA BIOSCIENCES INC · prev qtr: $13.80M
  • ATAI Ataibeckley Inc CVR · prev qtr: $10.54M
  • TENX TENAX THERAPEUTICS INC · prev qtr: $10.14M
  • PCSC PERCEPTIVE CAP SOLUTIONS COR · prev qtr: $8.08M
  • WVE WAVE LIFE SCIENCES INC · prev qtr: $7.84M
  • FDMT 4D MOLECULAR THERAPEUTICS IN · prev qtr: $6.33M

Insider Transactions (Form 4)

Latest RTW INVESTMENTS, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-09 Buy Orchestra BioMed Holdings, Inc. 1,200,000 $5.00 SEC filing
2026-07-21 J ALLURION TECHNOLOGIES, INC. 1,771 — SEC filing
2026-07-21 J ALLURION TECHNOLOGIES, INC. 19,934 — SEC filing
2026-07-21 J ALLURION TECHNOLOGIES, INC. 161,807 — SEC filing
2026-07-21 J ALLURION TECHNOLOGIES, INC. 209,254 — SEC filing
2026-04-27 Sell Orchestra BioMed Holdings, Inc. 32 $4.13 SEC filing
2026-04-27 Opt exercise Orchestra BioMed Holdings, Inc. 1,250,032 $0.00 SEC filing
2026-04-20 Buy Kailera Therapeutics, Inc. 500,000 $16.00 SEC filing

All insider transactions →

Fund Profile

RTW Investments, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 84 positions worth $11.71B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-78183 (status: Approved), registered 2013-06-13
  • Regulatory AUM (Form ADV): $14.14B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: rtwfunds.com

Portfolio Structure

  • 84 positions · $11.71B reported value (Q2 2026)
  • Top 10 holdings = 47.7% of reported value
  • Largest position: MDGL (MADRIGAL PHARMACEUTICALS INC) at 9.1%
  • Average position size: $139.44M

Sector Tilt

  • Health Care 99.1%
  • Industrials 0.4%
  • Information Technology 0.4%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 9 new, 24 added, 8 reduced, 13 exited
  • 43 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to biotech/healthcare (all top-10 holdings are Health Care), with net additions (4 adds vs. 3 reductions in top-10), suggesting bullish sentiment on innovative therapeutics. Weight increases in most holdings indicate confidence in pipeline catalysts or sector momentum. 2. Key moves: - Added: IRTC (+42.9% shares), TNGX (+1.1% shares), ERAS (+25.1% shares), TARS (+3.8% shares). - Reduced: INSM (-36.1% shares), SYRE (-13.2% shares), RDNT (-4.5% shares). - No change: PTGX, ARGX, CGON (held steady). 3. Portfolio structure: Active, high-conviction (concentrated top-10 holdings = 36.47% of AUM), with heavy bias toward clinical-stage biotech (elevated risk/reward). 4. Per-holding one-liner: - PTGX: Protagonist Therapeutics (unverified) – peptide-based therapeutics. - ARGX: Argenx (unverified) – autoimmune disease treatments. - CGON: CG Oncology (unverified) – immuno-oncology therapies. - IRTC: iRhythm (unverified) – wearable cardiac monitoring. - INSM: Insmed (unverified) – rare lung disease drugs. - TNGX: Tango Therapeutics (unverified) – oncology targeted therapies. - ERAS: Erasca (unverified) – cancer drug development. - SYRE: Spyre Therapeutics (unverified) – immunology pipeline. - RDNT: Radnet (unverified) – diagnostic imaging services. - TARS: Tarsus Pharmaceuticals (unverified) – eye disease treatments. 5. Style summary: Aggressive biotech fund with selective additions to high-growth clinical-stage names and reductions in overexposed positions.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 03:54

Sector Allocation

Health Care 99.0%
Technology 0.5%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 5.06M $713.07M 7.20%
7.20%
Hold
2 711.58K $682.35M 6.89%
6.89%
Hold
3 8.51M $603.60M 6.09%
6.09%
Hold
4 3.12M $354.50M 3.58%
3.58%
Add
5 3.10M $353.44M 3.57%
3.57%
Reduce
6 14.05M $350.51M 3.54%
3.54%
Add
7 22.45M $329.07M 3.32%
3.32%
Add
8 3.69M $328.68M 3.32%
3.32%
Reduce
9 4.63M $319.24M 3.22%
3.22%
Reduce
10 3.48M $273.88M 2.76%
2.76%
Add
11 10.35M $272.64M 2.75%
2.75%
Add
12 1.39M $266.32M 2.69%
2.69%
Add
13 1.48M $264.16M 2.67%
2.67%
Hold
14 3.30M $262.81M 2.65%
2.65%
Hold
15 3.14M $261.45M 2.64%
2.64%
Hold
16 600.00K $247.99M 2.50%
2.50%
Reduce
17 2.86M $188.63M 1.90%
1.90%
Hold
18 4.54M $184.62M 1.86%
1.86%
Hold
19 2.67M $171.06M 1.73%
1.73%
Hold
20 6.83M $170.35M 1.72%
1.72%
Add
21 312.82K $157.65M 1.59%
1.59%
Reduce
22 4.87M $147.51M 1.49%
1.49%
Hold
23 5.62M $146.21M 1.48%
1.48%
Hold
24 7.14M $143.96M 1.45%
1.45%
Hold
25 1.49M $141.06M 1.42%
1.42%
Hold
26 5.93M $139.33M 1.41%
1.41%
Hold
27 10.95M $136.20M 1.37%
1.37%
Add
28 942.68K $133.71M 1.35%
1.35%
Reduce
29 8.53M $128.20M 1.29%
1.29%
Add
30 10.78M $123.07M 1.24%
1.24%
Hold
31 715.33K $121.48M 1.23%
1.23%
Hold
32 13.52M $118.72M 1.20%
1.20%
Add
33 8.49M $112.43M 1.14%
1.14%
Add
34 3.18M $107.35M 1.08%
1.08%
Hold
35 1.62M $104.67M 1.06%
1.06%
Reduce
36 4.98M $102.03M 1.03%
1.03%
New
37 2.78M $98.71M 1.00%
1.00%
Hold
38 3.94M $95.23M 0.96%
0.96%
Hold
39 2.31M $73.93M 0.75%
0.75%
Hold
40 2.28M $71.36M 0.72%
0.72%
Add
41 1.66M $69.56M 0.70%
0.70%
Add
42 13.56M $66.04M 0.67%
0.67%
Hold
43 9.56M $59.44M 0.60%
Form 4 · 1 →
0.60%
Hold
44 6.72M $54.08M 0.55%
0.55%
Add
45 230.00K $50.96M 0.51%
0.51%
Hold
46 500.00K $48.62M 0.49%
0.49%
Hold
47 17.69M $46.52M 0.47%
0.47%
Hold
48 5.91M $42.70M 0.43%
0.43%
Add
49 1.51M $42.08M 0.42%
0.42%
Add
50 2.36M $36.29M 0.37%
0.37%
Hold

FAQ

What did RTW INVESTMENTS, LP buy in 2026-Q3?

In its 2026-Q3 13F filing, RTW INVESTMENTS, LP reported 81 equity positions worth $9.91B in aggregate; its largest disclosed positions were PTGX ($713.07M), ARGX ($682.35M), CGON ($603.60M).

How large is RTW INVESTMENTS, LP's portfolio?

RTW INVESTMENTS, LP reported $9.91B of long equity holdings across 81 positions as of 2026-Q3. Top-10 holdings account for 43.5% of reported value.

What is RTW INVESTMENTS, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/rtw-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →